Par Pharmaceutical Companies, Inc. (PRX) - Pending
  • Jul. 16, 2012, 8:24 AM

    TPG agrees to acquire Par Pharmaceutical (PRX) for $1.9B, or $50/share, which represents a 37% premium over Par's closing price on Friday. Shares +36% premarket. (PR)

    | Jul. 16, 2012, 8:24 AM
Company Description
Sector: Healthcare
Industry: Drugs - Generic
Country: United States